| Title: | Real-world experience in treatment of patients with non-small-cell lung cancer with BRAF or cMET exon 14 skipping mutations |
|---|
| Authors: | ID Janžič, Urška, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
ID Shalata, Walid (Author)
ID Szymczak, Katarzyna (Author)
ID Dziadziuszko, Rafal (Author)
ID Jakopović, Marko (Author)
ID Mountzios, Giannis (Author)
ID Płużański, Adam (Author)
ID Araújo, António (Author)
ID Charpidou, Andriani (Author)
ID Agbarya, Abed (Author) |
|---|
| Files: |  URL - Source URL, visit https://www.mdpi.com/1422-0067/24/16/12840
 PDF - Presentation file, download (305,90 KB)
MD5: CCADBE3C202C141A3B5DB28BD854F986
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83). |
|---|
| Keywords: | non-small-cell lung cancer, BRAF V600 mutation, cMET exon 14 skipping mutation, real-world data, targeted therapy, first-line therapy |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Submitted for review: | 15.07.2023 |
|---|
| Article acceptance date: | 15.08.2023 |
|---|
| Publication date: | 16.08.2023 |
|---|
| Publisher: | MDPI, 2000- |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | str. 1-14 |
|---|
| Numbering: | Vol. 24, iss. 16, [article no.] 12840 |
|---|
| Source: | International journal of molecular sciences |
|---|
| PID: | 20.500.12556/DiRROS-27797  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 1422-0067 |
|---|
| DOI: | 10.3390/ijms241612840 |
|---|
| COBISS.SI-ID: | 162782979 |
|---|
| Copyright: | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 30. 8. 2023;
|
|---|
| Publication date in DiRROS: | 25.02.2026 |
|---|
| Views: | 172 |
|---|
| Downloads: | 72 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
